In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

OncoMed closes $154mm Series B round; later adds on $15mm

Executive Summary

OncoMed Pharmaceuticals (anticancer stem cell antibodies) has raised $93mm through the second and final closing of its Series B round, bringing the total amount to $154mm. New investor Nomura Phase4 Ventures participated, along with returning buyers US Venture Partners, Latterell Venture Partners, the Vertical Group, Morgenthaler Ventures, Adams Street Partners, De Novo Ventures, Bay Partners, and development partner GlaxoSmithKline. Nomura Phase4's managing director will join OncoMed's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies